Lansoprazole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A proton pump inhibitor used for the short-term treatment of active duodenal ulcers, gastric ulcers, erosive esophagitis, GERD, and as part of multi-drug regimens for H. pylori eradication. Lansoprazole is also indicated for NSAID-associated gastric ulcer risk reduction.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A proton pump inhibitor used for the short-term treatment of active duodenal ulcers, gastric ulcers, erosive esophagitis, GERD, and as part of multi-drug regimens for H. NutriStack rates the supporting evidence as strong. Common adult dosing is 15–30 mg once daily for 4–8 weeks (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete magnesium, vitamin b12, calcium. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: healing of duodenal and gastric ulcers, treatment of erosive esophagitis, symptomatic gerd relief. 10 sources indexed (1995–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Suppresses gastric acid secretion by irreversibly blocking the hydrogen/potassium ATPase (H+/K+ ATPase) proton pump on gastric parietal cells. After absorption and accumulation in the acidic environment of the parietal cell canaliculus, lansoprazole is converted to its active sulfenamide form, which binds to cysteine residues on the proton pump.3,7
Dosing & protocol.
Take 30 minutes before eating; orally disintegrating tablets should be placed on the tongue and allowed to dissolve
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Magnesium
SignificantChronic acid suppression impairs active intestinal magnesium transport, especially via TRPM6/7-mediated uptake.
Vitamin B12
ModerateReduced gastric acid impairs release of food-bound vitamin B12 from proteins, lowering long-term absorption.
Calcium
ModerateLower gastric acidity reduces dissolution and absorption of less-soluble calcium salts, especially calcium carbonate.
Iron
ModerateReduced gastric acidity lowers conversion and solubility of non-heme iron, decreasing long-term absorption.
Full safety detail.
Side effects
- Diarrhea
- Abdominal pain
- Nausea
- Headache
- Constipation
- Vitamin B12 malabsorption with chronic use
- Hypomagnesemia with prolonged use
- Increased risk of C. difficile infection
- Increased risk of bone fractures with long-term use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
4- 1Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trialsPMIDChandan S, Deliwala S, Mohan BP et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
Chandan S, Deliwala S, Mohan BP et al.. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2023
- 2Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysisPMIDBazzoli F, Pozzato P, Zagari M et al. · Helicobacter · 1998
Bazzoli F, Pozzato P, Zagari M et al.. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Helicobacter. 1998
- 3Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysisPMIDTunis SR, Sheinhait IA, Schmid CH et al. · Clinical therapeutics · 1997
Tunis SR, Sheinhait IA, Schmid CH et al.. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clinical therapeutics. 1997
- 4Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcerPMIDPoynard T, Lemaire M, Agostini H · European journal of gastroenterology & hepatology · 1995
Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. European journal of gastroenterology & hepatology. 1995
Randomized controlled trials
1- 5Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 TrialPMIDShin CM, Choi SC, Cho JW et al. · Neurogastroenterology and motility · 2025
Shin CM, Choi SC, Cho JW et al.. Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial. Neurogastroenterology and motility. 2025
Reference material
5- 6Sachar H et al. Proton pump inhibitors: risks of long-term use. J Fam Pract. 2013.Source linkedPMID
- 7Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997.Source linkedPMID
- 8Vakil N et al. The Montreal definition and classification of gastroesophageal reflux disease. Am J Gastroenterol. 2006.Source linkedPMID
- 9Hong S, Ju JH, Lee SH et al.. Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer. Gut and liver. 2025Source linkedPMID
- 10Xiao Y, Zhang S, Dai N et al.. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020Source linkedPMID
Common questions.
Quick answers about Lansoprazole, drawn from the data on this page.
What is Lansoprazole?
A proton pump inhibitor used for the short-term treatment of active duodenal ulcers, gastric ulcers, erosive esophagitis, GERD, and as part of multi-drug regimens for H. pylori eradication. Lansoprazole is also indicated for NSAID-associated gastric ulcer risk reduction.
What is Lansoprazole used for?
Commonly cited benefits of Lansoprazole include: Healing of duodenal and gastric ulcers; Treatment of erosive esophagitis; Symptomatic GERD relief; H. pylori eradication (combination therapy); NSAID-associated gastric ulcer risk reduction. NutriStack rates the overall evidence as strong.
What is a typical dose of Lansoprazole?
A typical adult dose of Lansoprazole is 15–30 mg once daily for 4–8 weeks (as prescribed by your physician). The commonly recommended form is Delayed-release capsule or orally disintegrating tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Lansoprazole?
Reported side effects include diarrhea, abdominal pain, nausea, headache, constipation, vitamin b12 malabsorption with chronic use. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Lansoprazole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Lansoprazole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.